^
    Back
    Association details:
    Biomarker:GHR-ALK fusion
    Cancer:Lung Adenocarcinoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    J Int Med Res
    Title:

    A novel GHR-ALK fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report

    Published date:
    09/30/2021
    Excerpt:
    This case describes a 63-year-old woman diagnosed with metastatic LUAD....Next-generation sequencing identified a novel GHR-ALK fusion in the plasma of the patient. The patient was treated again with crizotinib, but the disease progressed again 2 months later.
    DOI:
    10.1177/03000605211044652